This enduring dialogue will focus on improving the detection, differentiation, and management of ocular toxicities associated with oral SERDs in patients with HR-positive, HER2-negative metastatic breast cancer. As a result of this educational activity, learners should be better able to: 1. Recognize the implications of using oral SERDs in HR-positive, HER2-negative breast cancer for ophthalmic practice; 2. Describe the ocular toxicities associated with oral SERDs used in breast cancer treatment; and, 3. Apply multidisciplinary strategies to facilitate the detection and management of ocular toxicities in patients receiving oral SERDs. Learners will have access to downloadable slides and podcast.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 27 Trinity Place, Suite 185
Pricing
99% of listed courses are free
156 of 157 courses listed here are free.
Collected from the provider’s public pages
Specialties served/covered
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Critical Care Medicine
- Dermatology
- Diagnostic Radiology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General Internal Medicine
- General Pediatrics
- General Surgery
- Gynecologic Oncology
- Hematology
- Infectious Disease
- Interventional Cardiology
- Maternal-Fetal Medicine
- Medical Oncology
- Nephrology
- Neurocritical Care
- Neurology
- Neuromuscular Medicine
- Obstetrics & Gynecology
- Ophthalmology
- Pediatric Gastroenterology
- Pediatric Infectious Diseases
- Pulmonary Disease
- Rheumatology
- Sleep Medicine
- Surgical Oncology
- Transplant Hepatology
- Urological Oncology
- Urology
- Vascular Neurology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Pathology & Lab
- Pediatrics
- Primary care
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Microlearning
- includes Podcast / audio
- Credit · Up to 0.5 credits
- Commercial Support
-
ReleasedOct 15, 2025
-
Last day to claim creditOct 15, 2026 4 days left
-
Answers in CME Inc. (AiCME) Integrating ESR1m Testing and Novel Oral SERDS Into Multidisciplinary Workflows: Regional Guidance for HR+, HER2- Advanced Breast Cancer
-
Answers in CME Inc. (AiCME) Bridging Clinic and OR: A Dialogue on the Emerging Role of Neoadjuvant HER2-Directed ADCs in HER2+ Breast Cancer
-
Answers in CME Inc. (AiCME) From Theory to Practice: Integrating TROP2 ADCs in HR+/HER2- Breast Cancer
